Exelixis, Inc. (EXEL)
51.86
-0.84
(-1.58%)
USD |
NASDAQ |
Jun 08, 15:36
Exelixis EPS Diluted (Quarterly) : 0.7873 for March 31, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Merck & Co., Inc. | -1.715 |
| Catalyst Pharmaceuticals, Inc. | 0.5022 |
| Madrigal Pharmaceuticals, Inc. | -3.251 |
| Krystal Biotech, Inc. | 1.833 |
| ACADIA Pharmaceuticals, Inc. | 0.0211 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 210.47M |
| Revenue (Quarterly) | 610.81M |
| Total Expenses (Quarterly) | 400.34M |
| Enterprise Value | 12.76B |
| Gross Profit Margin (Quarterly) | 96.73% |
| Profit Margin (Quarterly) | 34.46% |
| Earnings Yield | 5.82% |
| Operating Earnings Yield | 6.67% |
| Normalized Earnings Yield | 5.917 |